Hua Medicine 2
A New Kind of Glucokinase Activator
Through close collaboration with some of China’s top diabetes, as well as internationally renowned diabetes experts, Hua Medicine has reached a very good understanding on how to design the right Glucokinase Activator for diabetes treatment. Hua Medicine are changing the paradigm of diabetic treatment from simply lowering blood glucose to actually repairing defects in of glucose regulation in the body as well as remodelling glucose homeostasis. The overall aim is to develop the next generation in Type 2 Diabetes treatment.
Dorzagliatin is a novel drug. It has a different clinical profile to previous Glucokinase Activators. One of Dorzagliatin’s unique features is that, at molecular level, it shows very hypoglycae enzyme kinetics, which make it a glucose dependent Glucokinase Activators, avoiding hypoglycaemia. Phase 2 studies have emphasized it’s potent and sustained efficacy as well as safety profiles, including low incidence of hypoglycaemia, no lipid changes, no elevated liver enzyme, and no cardiovascular adverse effects.